A Phase 2 Extension of Study GCS-100-CS-4003

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Chronic Kidney Disease
Interventions
DRUG

GCS-100

3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.

Trial Locations (5)

28801

Mountain Kidney and Hypertension Associates, PA, Asheville

78215

Clinical Advancement Center, PLLC, San Antonio

80230

Denver Nephrology, Denver

85284

Southwest Clinical Research Institute, LLC, Tempe

91942

California Institute of Renal Research, La Mesa

All Listed Sponsors
lead

La Jolla Pharmaceutical Company

INDUSTRY

NCT02333955 - A Phase 2 Extension of Study GCS-100-CS-4003 | Biotech Hunter | Biotech Hunter